AddLife AB (publ) AI Price Prediction

With EPS of 5.87 and a PE ratio of 23.45, AddLife AB (publ) appears reasonably valued for a profitable, established business, but not deeply discounted. The valuation suggests the market still prices in some growth or resilience despite recent price weakness. Without detailed revenue and margin history, profitability looks solid but not clearly accelerating.

• Positive EPS of 5.87 indicates the company is generating consistent earnings and is not in a turnaround or loss-making phase.
• A PE ratio of 23.45 is in a moderate range for a healthcare/medtech-related name, implying the market is not pricing in extreme distress but also not assigning a high-growth multiple.
• The combination of positive earnings and a mid‑20s PE suggests stable, but not clearly high-growth, profitability; the stock’s recent decline appears more sentiment/technical than earnings-collapse driven based on the data provided.

Overall, AddLife AB (publ) presents a mixed picture: technically oversold within a still‑positive long-term trend, but with muted alternative data signals and only moderately attractive valuation. The setup leans toward a potential technical rebound, yet there is little evidence from hiring, web traffic, or social media that a strong fundamental acceleration is underway. On balance, the outlook is neutral with a slight tactical bias toward a short-term bounce rather than a clear long-term re‑rating.

• Technical indicators are supportive of a potential near-term recovery after a sharp, likely overdone, pullback, while the long-term trend remains intact above the 200‑day moving average.
• Fundamentals appear stable but not clearly high-growth, and alternative data show limited expansion signals, tempering the case for a strongly bullish long-term stance at this stage.